Regen BioPharma(OTC) RGBP

Regen BioPharma develops therapies that aim to help cancer and autoimmune disease patients. Its products focus on activating or suppressing the immune system. The company licenses its technology to partners in healthcare and veterinary fields.

Lab Bench to Bedside: Regen’s Main Offerings

• HemaXellerate: Cell therapy for bone marrow regeneration in severe blood disorders; 0% of revenue (pre-commercial).
• dCellVax: Immune cell therapy targeting cancer, especially breast cancer; 0% of revenue (pre-commercial).
• tCellVax: Therapy to boost immune response against tumors; 0% of revenue (pre-commercial).
• DiffronC: Drug designed to activate immune cells to fight cancer; 0% of revenue (pre-commercial).
• DuraCar: CAR-T cell therapy for solid tumors; 0% of revenue (pre-commercial).
• Licensing Agreements: All revenue (100%) comes from licensing intellectual property to Zander Therapeutics and Oncology Pharma.

Growth Spurts and Side Quests

• Signed licensing deal with Zander Therapeutics for veterinary uses in 2015.
• Entered agreement with Oncology Pharma for cancer vaccine rights in 2021.
• Intended to apply for Orphan Drug status for HemaXellerate as of 2024.
• Focused on early-stage development and licensing, not direct commercialization.

What Makes Regen BioPharma Stand Out

The company holds patents for targeting NR2F6, a novel immune checkpoint. Its business model centers on early-stage development and licensing, reducing late-stage risk. Regen relies on a single employee and external consultants for operations.

Five Things You Need to Know

• Revenue was $236,560 in fiscal 2024, flat from 2023 (0% change).
• Operating loss was $417,221 in fiscal 2024, compared to $686,950 in fiscal 2023.
• Cash balance was $716 as of September 30, 2024, compared to $121,037 as of September 30, 2023.
• All revenue comes from two licensing deals; no product sales reported.
• Working capital deficit was $5,235,105 as of September 30, 2024.

Bottom Line

Regen BioPharma remains a pre-commercial biotech focused on licensing its early-stage therapies. The company faces significant financial and operational challenges as it seeks partners and funding.